Quantitative proteomic landscape of unstable atherosclerosis identifies molecular signatures and therapeutic targets for plaque stabilization.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
13 03 2023
Historique:
received: 18 07 2022
accepted: 24 02 2023
entrez: 14 3 2023
pubmed: 15 3 2023
medline: 16 3 2023
Statut: epublish

Résumé

Atherosclerotic plaque rupture leading to myocardial infarction is a major global health burden. Applying the tandem stenosis (TS) mouse model, which distinctively exhibits the characteristics of human plaque instability/rupture, we use quantitative proteomics to understand and directly compare unstable and stable atherosclerosis. Our data highlight the disparate natures and define unique protein signatures of unstable and stable atherosclerosis. Key proteins and pathway networks are identified such as the innate immune system, and neutrophil degranulation. The latter includes calprotectin S100A8/A9, which we validate in mouse and human unstable plaques, and we demonstrate the plaque-stabilizing effects of its inhibition. Overall, we provide critical insights into the unique proteomic landscape of unstable atherosclerosis (as distinct from stable atherosclerosis and vascular tissue). We further establish the TS model as a reliable preclinical tool for the discovery and testing of plaque-stabilizing drugs. Finally, we provide a knowledge resource defining unstable atherosclerosis that will facilitate the identification and validation of long-sought-after therapeutic targets and drugs for plaque stabilization.

Identifiants

pubmed: 36914713
doi: 10.1038/s42003-023-04641-4
pii: 10.1038/s42003-023-04641-4
pmc: PMC10011552
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

265

Informations de copyright

© 2023. The Author(s).

Références

J Proteome Res. 2018 Jan 5;17(1):164-176
pubmed: 29129081
Proteomics. 2019 Apr;19(8):e1800148
pubmed: 30582284
Br J Pharmacol. 2022 Mar;179(5):979-997
pubmed: 33368184
Circ Res. 2014 Jun 6;114(12):1852-66
pubmed: 24902970
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Cell Metab. 2013 May 7;17(5):695-708
pubmed: 23663738
J Extracell Vesicles. 2021 Nov;10(13):e12164
pubmed: 34817906
J Innate Immun. 2012;4(1):31-40
pubmed: 21912088
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Circulation. 2020 Mar 31;141(13):1080-1094
pubmed: 31941367
Cells. 2022 Jan 11;11(2):
pubmed: 35053354
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
J Clin Invest. 2017 Jun 1;127(6):2133-2147
pubmed: 28504650
J Proteome Res. 2019 Feb 1;18(2):623-632
pubmed: 30450911
Nat Commun. 2017 Jul 13;8(1):75
pubmed: 28706202
Methods Mol Biol. 2015;1339:333-8
pubmed: 26445800
Circ Res. 2019 Apr 26;124(9):1297-1299
pubmed: 31021730
Cardiovasc Res. 2021 Jan 21;117(2):435-449
pubmed: 32267921
Circ Res. 2018 Jun 8;122(12):1632-1634
pubmed: 29880495
Proteomics Clin Appl. 2015 Jun;9(5-6):453-68
pubmed: 25641766
Methods Mol Biol. 2018;1788:165-175
pubmed: 28994030
Circ Res. 2013 Jul 19;113(3):252-65
pubmed: 23748430
Sci Rep. 2016 May 20;6:26231
pubmed: 27198765
Pathol Int. 2020 Jun;70(6):309-322
pubmed: 32166823
Circulation. 2009 Aug 4;120(5):427-36
pubmed: 19620505
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Hum Genomics. 2016 Jun 02;10(1):14
pubmed: 27251057
Cardiovasc Res. 2021 Feb 22;117(3):918-929
pubmed: 32251516
Proteomics Clin Appl. 2014 Aug;8(7-8):631-5
pubmed: 24828403
N Engl J Med. 2011 Jan 20;364(3):226-35
pubmed: 21247313
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1282-92
pubmed: 20554950
Mol Psychiatry. 2022 Mar;27(3):1416-1434
pubmed: 34789849
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
Nat Biotechnol. 2021 Dec;39(12):1563-1573
pubmed: 34239088
Circ Res. 2020 Sep 25;127(8):997-1022
pubmed: 32762496
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1842-8
pubmed: 20595650
Eur Heart J. 2018 Sep 14;39(35):3301-3310
pubmed: 30219874
J Am Heart Assoc. 2022 Jan 4;11(1):e022761
pubmed: 34970931
Mol Cell Proteomics. 2012 Mar;11(3):M111.013722
pubmed: 22021278
Eur J Pharmacol. 2017 Dec 5;816:107-115
pubmed: 28435093
J Clin Invest. 2017 Apr 3;127(4):1546-1560
pubmed: 28319050
Circulation. 2011 Mar 22;123(11):1216-26
pubmed: 21382888

Auteurs

Yung-Chih Chen (YC)

Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Central Clinical School, Monash University, Melbourne, VIC, Australia.
Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia.

Meaghan Smith (M)

Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Ya-Lan Ying (YL)

Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Central Clinical School, Monash University, Melbourne, VIC, Australia.

Manousos Makridakis (M)

Proteomics Research Unit, Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Jonathan Noonan (J)

Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Central Clinical School, Monash University, Melbourne, VIC, Australia.
Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia.

Peter Kanellakis (P)

Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Alin Rai (A)

Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia.
Molecular Proteomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, VIC, Australia.

Agus Salim (A)

Department of Bioinformatics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Andrew Murphy (A)

Central Clinical School, Monash University, Melbourne, VIC, Australia.
Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia.
Haematopoiseis and Leukocyte Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Alex Bobik (A)

Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Department of Immunology, Monash University, Centre for Inflammatory Disease, School of Clinical Sciences, Monash Health, Melbourne, VIC, Australia.

Antonia Vlahou (A)

Proteomics Research Unit, Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

David W Greening (DW)

Central Clinical School, Monash University, Melbourne, VIC, Australia. David.Greening@baker.edu.au.
Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia. David.Greening@baker.edu.au.
Molecular Proteomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. David.Greening@baker.edu.au.
Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, VIC, Australia. David.Greening@baker.edu.au.

Karlheinz Peter (K)

Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. Karlheinz.Peter@baker.edu.au.
Central Clinical School, Monash University, Melbourne, VIC, Australia. Karlheinz.Peter@baker.edu.au.
Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC, Australia. Karlheinz.Peter@baker.edu.au.
Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, VIC, Australia. Karlheinz.Peter@baker.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH